FridayOL

Cambridge, MA – August 22, 2025 – In a significant step forward in the ongoing fight against COVID-19, Moderna today announced that Health Canada has granted authorization for its updated mRNA vaccine, Spikevax®, specifically designed to target the emerging SARS-CoV-2 LP.8.1 variant. This approval paves the way for broader protection against this evolving strain for individuals aged six months and older.

The updated Spikevax vaccine represents a crucial adaptation to the virus’s continued evolution. The LP.8.1 variant, while not currently dominant, has demonstrated characteristics that warrant a targeted response to ensure continued efficacy of vaccines. Moderna’s research and development teams have worked diligently to formulate a vaccine that effectively counters this variant, offering enhanced protection against potential infection and severe illness.

“We are pleased to receive Health Canada’s authorization for our updated COVID-19 vaccine,” said a Moderna spokesperson. “This reflects our commitment to rapidly adapting to the evolving viral landscape and providing Canadians with the best possible protection. We understand the importance of staying ahead of new variants, and this updated vaccine is a vital tool in that effort.”

Key Highlights of the Approval:

• Variant Targeting: The vaccine is specifically formulated to target the SARS-CoV-2 LP.8.1 variant.
• Age Range: Approved for individuals aged six months and older, encompassing a wide range of the population.
• Timely Delivery: Moderna is on track to deliver the updated vaccine in time for the 2025-2026 vaccination season, allowing individuals to receive protection before the anticipated winter surge.
• mRNA Technology: Utilizes the proven mRNA technology that has demonstrated both safety and efficacy in previous COVID-19 vaccines.

The authorization follows a rigorous review of clinical trial data submitted by Moderna to Health Canada. The data demonstrated a strong immune response against the LP.8.1 variant, reinforcing the vaccine's potential to provide robust protection. Health Canada’s decision underscores the agency’s commitment to ensuring access to safe and effective vaccines.

Public health officials are encouraging individuals to stay informed about COVID-19 vaccination recommendations and to consult with their healthcare providers to determine the best course of action for their individual needs. The updated vaccine will be an important addition to the existing public health toolkit, helping to mitigate the impact of COVID-19 and protect vulnerable populations.

Moderna remains dedicated to ongoing research and development to address emerging variants and ensure the continued effectiveness of its vaccines in combating the COVID-19 pandemic. The company anticipates further updates on vaccine availability and distribution plans in the coming weeks.